Munger K, Levin L, Hollis B, Howard N, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832.
Article
PubMed
CAS
Google Scholar
Munger K, Ascherio A. Prevention and treatment of MS: studying the effects of vitamin D. Mult Scler J. 2011;17(12):1405–11.
Article
CAS
Google Scholar
Munger K, Åivo J, Hongell K, Soilu-Hänninen M, Surcel H, Ascherio A. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort. JAMA Neurol. 2016;73(5):515.
Article
PubMed
PubMed Central
Google Scholar
Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.
Article
PubMed
CAS
Google Scholar
ChemSpider | Search and share chemistry [Internet]. Chemspider.com. 2017 [cited 30 June 2016]. http://www.chemspider.com.
Conlan R, Sherman E. Unraveling the enigma of vitamin D [Internet]. National Academy of Sciences; 2000 [cited 28 June 2016]. http://www.nasonline.org/publications/beyond-discovery/vitamin-d.pdf.
Ascherio A, Munger K, Simon K. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9(6):599–612.
Article
PubMed
Google Scholar
Holick M. Vitamin D: a millenium perspective. J Cell Biochem. 2002;88(2):296–307.
Article
CAS
Google Scholar
Health Quality Ontario. Clinical Utility of Vitamin D Testing: An Evidence-Based Analysis. 2010 p. 1-93.
Wacker M, Holick M. Vitamin D—effects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5(1):111–48.
Article
PubMed
PubMed Central
CAS
Google Scholar
Holick M, Binkley N, Bischoff-Ferrari H, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.
Article
PubMed
CAS
Google Scholar
Yang L, Ma J, Zhang X, Fan Y, Wang L. Protective role of the vitamin D receptor. Cell Immunol. 2012;279(2):160–6.
Article
PubMed
CAS
Google Scholar
Hossein-nezhad A, Holick M. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88(7):720–55.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mora J, Iwata M, von Andrian U. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8(9):685–98.
Article
PubMed
PubMed Central
CAS
Google Scholar
Pierrot-Deseilligny C, Souberbielle J. Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther Adv Neurol Disor. 2013;6(2):81–116.
Article
CAS
Google Scholar
Ross A, Taylor C, Yaktine A, Del Valle H. Dietary reference intakes: calcium and vitamin D. Committee to review dietary reference intakes for vitamin D and calcium food and nutrition board [Internet]. Washington, D.C.: National Academy of Sciences; 2011 [cited 28 June 2016]. http://www.ncbi.nlm.nih.gov/books/NBK56070/pdf/TOC.pdf.
Houghton L, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. The Am J Clin Nutr. 2006;84(4):694–7.
Article
PubMed
CAS
Google Scholar
Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem. 2003;88(4):695–705.
Article
PubMed
CAS
Google Scholar
Holick M, Vitamin D. Deficiency. N Engl J Med. 2007;357(3):266–81.
Article
PubMed
CAS
Google Scholar
Heaney R. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004;80(6):1706S–9S.
Article
PubMed
CAS
Google Scholar
Heaney R, Davies K, Chen T, Holick M, Barger-Lux M. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutri. 2003;77(1):204–10.
Article
CAS
Google Scholar
Burton J, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kimball S, Ursell M, O’Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86(3):645–51.
Article
PubMed
CAS
Google Scholar
Smolders J, Peelen E, Thewissen M, et al. Safety and T Cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One. 2010;5(12):e15235.
Article
PubMed
PubMed Central
CAS
Google Scholar
Bell D, Crooke M, Hay N, Glendenning P. Prolonged vitamin D intoxication: presentation, pathogenesis and progress. Int Med J. 2013;43(10):1148–50.
Article
CAS
Google Scholar
Fragoso Y, Adoni T, Damasceno A, et al. Unfavorable outcomes during treatment of multiple sclerosis with high doses of vitamin D. J Neurol Sci. 2014;346(1–2):341–2.
Article
PubMed
CAS
Google Scholar
Swank R, Lerstad O, Strøm A, Backer J. Multiple Sclerosis in Rural Norway. N Eng J Med. 1952;246(19):721–8.
Article
CAS
Google Scholar
Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand. 1970;46(4–5):455–83.
Article
PubMed
CAS
Google Scholar
van der Mei I, Ponsonby A, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology. 2001;20(3):168–74.
Article
PubMed
Google Scholar
Vukusic S, Van Bockstael V, Gosselin S, Confavreux C. Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry. 2006;78(7):707–9.
Article
Google Scholar
Pierrot-Deseilligny C, Souberbielle J. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis. Brain. 2010;133(7):1869–88.
Article
PubMed
Google Scholar
Orton S, Wald L, Confavreux C, et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology. 2011;76(5):425–31.
Article
PubMed
PubMed Central
Google Scholar
Kurtzke J, Beebe G, Norman J. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MIS. Neurology. 1985;35(5):672.
Article
PubMed
CAS
Google Scholar
Ascherio A, Munger K. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol. 2007;61(6):504–13.
Article
PubMed
CAS
Google Scholar
Lucas R, Ponsonby A, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011;76(6):540–8.
Article
PubMed
CAS
Google Scholar
Hauser S, Weiner H, Che C, Shapiro M, Gilles F, Letvin N. Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. J Immunol. 1984;132(3):1276–81.
PubMed
CAS
Google Scholar
Willer C. Timing of birth and risk of multiple sclerosis: population based study. BMJ. 2005;330(7483):120.
Article
PubMed
PubMed Central
Google Scholar
Fiddes B, Wason J, Sawcer S. Confounding in association studies: month of birth and multiple sclerosis. J Neurol. 2014;261(10):1851–6.
Article
PubMed
PubMed Central
Google Scholar
Rodríguez Cruz P, Matthews L, Boggild M, et al. Time- and region-specific season of birth effects in multiple sclerosis in the United Kingdom. JAMA Neurol. 2016;73(8):954.
Article
PubMed
Google Scholar
Munger K, Zhang S, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60–5.
Article
PubMed
CAS
Google Scholar
Nielsen N, Munger K, Stenager E, Ascherio A. Author response: neonatal vitamin D status and risk of multiple sclerosis: a population-based case-control study. Neurology. 2017;89(4):411.
Article
PubMed
Google Scholar
Mokry L, Ross S, Ahmad O, et al. Vitamin D and risk of multiple sclerosis: a mendelian randomization study. PLOS Med. 2015;12(8):e1001866.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gianfrancesco M, Stridh P, Rhead B, et al. Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology. 2017;88(17):1623–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jelinek G. Determining causation from observational studies: a challenge for modern neuroepidemiology. Front Neurol. 2017;8:1–3.
Article
Google Scholar
Rhead B, Bäärnhielm M, Gianfrancesco M, et al. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Gen. 2016;2(5):e97.
Article
CAS
Google Scholar
Ueda P, Rafatnia F, Bäärnhielm M, et al. Neonatal vitamin D status and risk of multiple sclerosis. Ann Neurol. 2014;76(3):338–46.
Article
PubMed
CAS
Google Scholar
Ascherio A, Munger K. Not too late to take vitamin D supplements. Ann Neurol. 2014;76(3):321–2.
Article
PubMed
CAS
Google Scholar
Pihl-Jensen G, Frederiksen J. 25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis. J Neurol. 2015;262(7):1646–54.
Article
PubMed
CAS
Google Scholar
Marrie R, Daumer M. A gestational dose of vitamin D per day keeps the MS doctor away. Neurology. 2016;88(1):13–4.
Article
PubMed
Google Scholar
Runia T, Hop W, de Rijke Y, Buljevac D, Hintzen R. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology. 2012;79(3):261–6.
Article
PubMed
CAS
Google Scholar
Mowry E, Krupp L, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol. 2010;67(5):618–24.
PubMed
CAS
Google Scholar
Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Ann Neurol. 2010;68(2):193–203.
PubMed
CAS
Google Scholar
Mowry E, Waubant E, McCulloch C, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72(2):234–40.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mowry E, Pelletier D, Gao Z, Howell M, Zamvil S, Waubant E. Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection. Eur J Neurol. 2015;23(2):327–32.
Article
PubMed
Google Scholar
Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler J. 2008;14(9):1220–4.
Article
CAS
Google Scholar
Harandi A, Shahbeigi S, Pakdaman H, Fereshtehnejad S, Nikravesh E, Jalilzadeh R. Association of serum 25(OH) vitamin D3 concentration with severity of multiple sclerosis. Iran J Neurol [Internet]. 2012 [cited 22 August 2017];11(2):54–58. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829240/.
Shahbeigi S, Pakdaman H, Fereshtehnejad S, Jalilzadeh G, Heydari M. Serum Vitamin D3 Concentration Correlates with the Severity of Multiple Sclerosis. Int J Prev Med. 2013;4(5):585–91.
PubMed
PubMed Central
Google Scholar
Martinelli V, Dalla Costa G, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler J. 2013;20(2):147–55.
Article
CAS
Google Scholar
Koven N, Cadden M, Murali S, Ross M. Vitamin D and long-term memory in multiple sclerosis. Cogn Behav Neurol. 2013;26(3):155–60.
Article
PubMed
Google Scholar
Ascherio A, Munger K, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306–14.
Article
PubMed
PubMed Central
Google Scholar
Fitzgerald K, Munger K, Köchert K, et al. Association of Vitamin D Levels With multiple sclerosis activity and progression in patients receiving interferon Beta-1b. JAMA Neurol. 2015;72(12):1458.
Article
PubMed
Google Scholar
Kappos L, Polman C, Freedman M, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242–9.
Article
PubMed
CAS
Google Scholar
Kappos L, Freedman M, Polman C, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389–97.
Article
PubMed
CAS
Google Scholar
Kappos L, Freedman M, Polman C, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987–97.
Article
PubMed
CAS
Google Scholar
McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121–7.
Article
PubMed
CAS
Google Scholar
Taylor B, Moses H, Paul F, Suarez G, Rametta M. Treatment of multiple sclerosis-relationship between Vitamin D and Interferon β-1b. Eur Neurol Rev. 2015;10(2):124.
Article
Google Scholar
Munger K, Köchert K, Simon K, et al. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann Clin Trans Neurol. 2014;1(8):605–17.
Article
CAS
Google Scholar
Stewart N, Simpson S, van der Mei I, et al. Interferon- and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology. 2012;79(3):254–60.
Article
PubMed
CAS
Google Scholar
Rotstein D, Healy B, Malik M, et al. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e167.
Article
PubMed
PubMed Central
Google Scholar
Loken-Amsrud K, Holmoy T, Bakke S, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-treatment. Neurology. 2012;79(3):267–73.
Article
PubMed
CAS
Google Scholar
Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest. 2011;40(6):627–39.
Article
PubMed
CAS
Google Scholar
Stein M, Liu Y, Gray O, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011;77(17):1611–8.
Article
PubMed
CAS
Google Scholar
Kampman M, Steffensen L, Mellgren S, Jørgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler J. 2012;18(8):1144–51.
Article
CAS
Google Scholar
Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int. 2012;2012:1–7.
Article
CAS
Google Scholar
Soilu-Hänninen M, Åivo J, Lindström B, et al. A randomised, double blind, placebo controlled trial with vitamin D3as an add on treatment to interferon β-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(5):565–71.
Article
PubMed
Google Scholar
Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: Preliminary findings of a randomized-controlled trial. Iran J Neurol. 2015;14(2):67–73.
PubMed
PubMed Central
Google Scholar
Jelinek G, Marck C, Weiland T, Pereira N, van der Meer D, Hadgkiss E. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis. BMC Neurol. 2015;15(1):1–6.
Article
CAS
Google Scholar
Laursen J, Søndergaard H, Sørensen P, Sellebjerg F, Oturai A. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Mult Scler Rel Dis. 2016;10:169–73.
Article
Google Scholar
Darwish H, Haddad R, Osman S, et al. Effect of vitamin D replacement on cognition in multiple sclerosis patients. Sci Rep. 2017;7:45926.
Article
PubMed
PubMed Central
CAS
Google Scholar
Smolders J, Hupperts R, Vieth R, et al. High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a. In: Presented at the European Committee for Treatment and Research in Multiple Sclerosis conference. London, England, September 14–17, 2016. Abstract S166.
Camu W, Pierrot-Deseilligny C, Hautecoeur P, et al. Cholecalciferol supplementation in relapsing multiple sclerosis patients treated with subcutaneous interferon beta-1a: a randomized, controlled trial. In: Presented at the European Committee for treatment and research in multiple sclerosis conference. London, England, September 14–17, 2016. Abstract P750.
Sotirchos E, Bhargava P, Eckstein C, et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology. 2015;86(4):382–90.
Article
PubMed
CAS
Google Scholar
Fox R, Miller D, Phillips J, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97.
Article
PubMed
CAS
Google Scholar
Cohen J, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.
Article
PubMed
CAS
Google Scholar
James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan S. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler J. 2013;19(12):1571–9.
Article
CAS
Google Scholar
ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2017 [cited 30 June 2016]. http://www.clinicaltrials.gov.
Dörr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials. 2012;13(15):1–6.
Google Scholar
Bhargava P, Cassard S, Steele S, et al. The Vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials. 2014;39(2):288–93.
Article
PubMed
Google Scholar